JP2005511532A5 - - Google Patents

Download PDF

Info

Publication number
JP2005511532A5
JP2005511532A5 JP2003535776A JP2003535776A JP2005511532A5 JP 2005511532 A5 JP2005511532 A5 JP 2005511532A5 JP 2003535776 A JP2003535776 A JP 2003535776A JP 2003535776 A JP2003535776 A JP 2003535776A JP 2005511532 A5 JP2005511532 A5 JP 2005511532A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally
hydrogen
substituted
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003535776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511532A (ja
Filing date
Publication date
Priority claimed from GBGB0124941.6A external-priority patent/GB0124941D0/en
Application filed filed Critical
Publication of JP2005511532A publication Critical patent/JP2005511532A/ja
Publication of JP2005511532A5 publication Critical patent/JP2005511532A5/ja
Pending legal-status Critical Current

Links

JP2003535776A 2001-10-17 2002-10-16 ５’−カルバモイル−１，１−ビフェニル−４−カルボキサミド誘導体及びそのｐ３８キナーゼ阻害薬としての使用 Pending JP2005511532A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124941.6A GB0124941D0 (en) 2001-10-17 2001-10-17 Chemical compounds
PCT/EP2002/011577 WO2003032972A1 (en) 2001-10-17 2002-10-16 5’-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2005511532A JP2005511532A (ja) 2005-04-28
JP2005511532A5 true JP2005511532A5 (enExample) 2006-01-05

Family

ID=9924035

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003535776A Pending JP2005511532A (ja) 2001-10-17 2002-10-16 ５’−カルバモイル−１，１−ビフェニル−４−カルボキサミド誘導体及びそのｐ３８キナーゼ阻害薬としての使用

Country Status (6)

Country Link
US (1) US7208629B2 (enExample)
EP (1) EP1435936A1 (enExample)
JP (1) JP2005511532A (enExample)
AU (1) AU2002362895A1 (enExample)
GB (1) GB0124941D0 (enExample)
WO (1) WO2003032972A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
JP4524072B2 (ja) * 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
JP4472349B2 (ja) * 2002-02-12 2010-06-02 スミスクライン ビーチャム コーポレーション ｐ３８阻害薬として有用なニコチンアミド誘導体
GB0209891D0 (en) * 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
ATE439837T1 (de) 2003-06-03 2009-09-15 Novartis Ag 5-gliedrige heterocyclische p-38 inhibitoren
HRP20110757T1 (hr) 2003-06-26 2011-11-30 Novartis Ag Inhibitori kinaze p38 bazirani na 5-članom heterociklu
MXPA06000915A (es) * 2003-07-25 2006-03-30 Novartis Ag Inhibidores de quinasa p-38.
CN103275058B (zh) 2003-08-06 2016-02-24 西诺米克斯公司 调味剂、味道调节剂、促味剂、味觉增强剂、鲜味剂或甜味剂和/或增强剂及其用途
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
JP2007506741A (ja) * 2003-09-23 2007-03-22 メルク　エンド　カムパニー　インコーポレーテッド 向代謝性グルタミン酸受容体のピラゾール系調節剤
US20070208166A1 (en) * 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use
GB0402137D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402138D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
US7326732B2 (en) * 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
TW200628153A (en) * 2004-10-05 2006-08-16 Smithkline Beecham Corp Novel compounds
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
US20080096905A1 (en) * 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
WO2007017687A2 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
WO2007031791A1 (en) * 2005-09-16 2007-03-22 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
RU2452729C2 (ru) * 2005-09-16 2012-06-10 Арроу Терапьютикс Лимитед Бифенильные производные и их применение при лечении гепатита с
JP2009528344A (ja) * 2006-02-28 2009-08-06 アストラゼネカ・アクチエボラーグ インドール誘導体の新規な塩及び医薬におけるその使用
EP2038253A1 (en) * 2006-05-30 2009-03-25 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
GB0612026D0 (en) 2006-06-16 2006-07-26 Smithkline Beecham Corp New use
MX2009000286A (es) 2006-06-26 2009-03-20 Procter & Gamble Inhibidores de prolil hidroxilasa y metodos de uso.
EP2238101A2 (en) * 2008-02-05 2010-10-13 Asterand Uk Limited Difluorobiphenylamide derivatives for the treatment of ocular hypertension
MX2013014310A (es) 2011-06-06 2014-01-23 Akebia Therapeutics Inc Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer.
NO2686520T3 (enExample) 2011-06-06 2018-03-17
CN114404414A (zh) 2013-06-13 2022-04-29 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
EP3247355A4 (en) 2015-01-23 2018-06-13 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
EA036920B1 (ru) 2015-04-01 2021-01-15 Экебиа Терапьютикс, Инк. Композиции и способы для лечения анемии
US10550073B2 (en) * 2015-09-30 2020-02-04 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Benzamide derivative
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP2021501130A (ja) 2017-10-05 2021-01-14 フルクラム セラピューティクス，インコーポレイテッド ＤＵＸ４の発現を低減するためのｐ３８阻害剤の使用
TW202406895A (zh) 2018-05-09 2024-02-16 美商阿克比治療有限公司 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
CN109824582B (zh) * 2019-01-18 2020-06-19 西安交通大学 一种丙氨酸衍生物及其制备方法和应用
CN109824584B (zh) * 2019-01-18 2020-08-18 西安交通大学 一种含有叔亮氨酸的类肽类化合物及其制备方法和应用
CN109734660B (zh) * 2019-01-18 2020-07-28 西安交通大学 一种含有叔丁基取代的丝氨酸的类肽类化合物及其制备方法和应用
CN109824581B (zh) * 2019-01-18 2020-08-18 西安交通大学 一种含有丙氨酸的类肽类化合物以及其制备方法和应用
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
KR102298450B1 (ko) * 2021-01-29 2021-09-08 (주)프레이저테라퓨틱스 p38 MAP 키나아제 억제제로 항염증 활성을 나타내는 신규 화합물

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
EP0346841A3 (de) 1988-06-16 1991-01-09 Ciba-Geigy Ag 1-Aryl-naphthoesäureamide und diese enthaltende mikrobizide Mittel
MX16687A (es) 1988-07-07 1994-01-31 Ciba Geigy Ag Compuestos de biarilo y procedimiento para su preparacion.
EP0430033A3 (en) 1989-11-24 1991-09-11 Ciba-Geigy Ag Microbicidal agents
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ES2162792T3 (es) 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
GB2273930A (en) 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
TW240217B (enExample) 1992-12-30 1995-02-11 Glaxo Group Ltd
IL108630A0 (en) 1993-02-18 1994-05-30 Fmc Corp Insecticidal substituted 2,4-diaminoquinazolines
GB2276162A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benazilide derivatives
GB2276161A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benzanilide derivatives
CN1129933A (zh) 1993-08-31 1996-08-28 辉瑞大药厂 5-芳基吲哚衍生物
WO1995006644A1 (en) 1993-09-03 1995-03-09 Smithkline Beecham Plc Amide derivatives as 5ht1d receptor antagonists
EP0724580A1 (en) 1993-10-19 1996-08-07 Smithkline Beecham Plc Benzanilide derivatives as 5ht-1d receptor antagonists
JPH09506101A (ja) 1993-12-07 1997-06-17 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ｄ拮抗薬として有用な複素環式ビフェニリルアミド類
GB9326008D0 (en) 1993-12-21 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9408577D0 (en) 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
JPH09512804A (ja) 1994-05-06 1997-12-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ１ｄアンタゴニストとして有用なビフェニルカルボキシアミド類
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
EP0819127A1 (en) 1995-04-04 1998-01-21 Glaxo Group Limited IMIDAZO [1,2-a]PYRIDINE DERIVATIVES
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
CA2226849A1 (en) 1995-07-10 1997-01-30 Zenon Lysenko Stable polynitrile oxides and their use as curing agent especially for latex
EP1304322A3 (en) 1995-08-22 2003-11-19 Japan Tobacco Inc. Carboxylic acid compound and use thereof
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6323227B1 (en) 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
ES2205167T3 (es) 1996-01-11 2004-05-01 Smithkline Beecham Corporation Nuevos compuestos de imidazol sustituidos.
FR2754260B1 (fr) 1996-10-04 1998-10-30 Adir Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5945418A (en) 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
PL336990A1 (en) 1997-05-22 2000-07-31 Searle & Co 3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38
US6087496A (en) 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
EP1023066A4 (en) 1997-06-13 2001-05-23 Smithkline Beecham Corp NEW PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUND
AU7976998A (en) 1997-06-19 1999-01-04 Du Pont Merck Pharmaceutical Company, The (amidino)6-membered aromatics as factor xa inhibitors
US6060491A (en) 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
US6251914B1 (en) 1997-07-02 2001-06-26 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
CA2303152A1 (en) 1997-09-05 1999-03-18 Glaxo Group Limited 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors
KR100340273B1 (ko) 1997-10-14 2002-06-14 야마모토 카즈모토 비페닐-5-알칸산 유도체 및 이의 용도
IL136737A0 (en) 1997-12-22 2001-06-14 Bayer Ag Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
JPH11211888A (ja) 1998-01-26 1999-08-06 Toyo Ink Mfg Co Ltd 放射線遮蔽材および放射線装置
DE19817461A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Benzamide, deren Herstellung und Anwendung
ATE282590T1 (de) 1998-05-15 2004-12-15 Astrazeneca Ab Benzamid-derivate zur behandlung cytokin- vermittelter krankheiten
US6448257B1 (en) 1998-05-22 2002-09-10 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6130235A (en) 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
US6867209B1 (en) 1998-05-22 2005-03-15 Scios, Inc. Indole-type derivatives as inhibitors of p38 kinase
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
IL141724A0 (en) 1998-08-28 2002-03-10 Scios Inc INHIBITORS OF P38-α KINASE
JP2002526482A (ja) 1998-09-18 2002-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
CN1263755C (zh) 1998-11-03 2006-07-12 葛兰素集团有限公司 作为选择性cox－2抑制剂的吡唑并吡啶衍生物
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US6545054B1 (en) 1999-02-11 2003-04-08 Millennium Pharmaceuticals, Inc. Alkenyl and alkynyl compounds as inhibitors of factor Xa
DE69915519T2 (de) 1999-02-27 2005-02-03 Glaxo Group Ltd., Greenford Pyrazolopyridine
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
US6509361B1 (en) 1999-05-12 2003-01-21 Pharmacia Corporation 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors
JP2003500376A (ja) 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子の阻害剤
JP2003500386A (ja) 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
CA2374820A1 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. Inhibitors of factor xa
DE19932571A1 (de) 1999-07-13 2001-01-18 Clariant Gmbh Verfahren zur Herstellung von Biarylen unter Palladophosphacyclobutan-Katalyse
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US6576632B1 (en) 1999-08-27 2003-06-10 Pfizer Inc Biaryl compounds useful as anticancer agents
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
MXPA01007019A (es) 1999-11-10 2002-09-18 Johnson & Johnson 2-aril-3-(heteroaril)-imidazo[1,2-a]pirimidinas, sustituidas y composiciones farmaceuticas relacionados y metodos.
WO2001070695A1 (en) 2000-03-22 2001-09-27 Vertex Pharmaceuticals Incorporated Pyridine derivatives as inhibitors of p38
EP1283208A4 (en) 2000-05-18 2003-08-13 Daiichi Seiyaku Co NEW BENZOFURAN DERIVATIVES
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
DK1363910T3 (da) 2000-11-17 2006-06-26 Bristol Myers Squibb Co Fremgangsmåder til behandling af P39-kinase-associerede tilstande og pyrrolotriazinforbindelser, der er anvendelige som kinase-inhibitorer
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE60210755T2 (de) 2001-03-09 2006-11-16 Pfizer Products Inc., Groton Triazolopyridine als entzündungshemmende mittel
ES2332090T3 (es) 2001-04-06 2010-01-26 Biocryst Pharmaceuticals, Inc. Compuestos biarilicos como inhibidores de serina proteasa.
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
GB0124848D0 (en) 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
GB0124928D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
JP4472349B2 (ja) 2002-02-12 2010-06-02 スミスクライン ビーチャム コーポレーション ｐ３８阻害薬として有用なニコチンアミド誘導体
US20030225089A1 (en) 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
GB0209891D0 (en) 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US20040116479A1 (en) 2002-10-04 2004-06-17 Fortuna Haviv Method of inhibiting angiogenesis
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
MXPA06000915A (es) 2003-07-25 2006-03-30 Novartis Ag Inhibidores de quinasa p-38.
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
FR2864454B1 (fr) 2003-12-30 2006-02-03 Centre Nat Rech Scient Procede de dissolution de nanotubes de carbone et ses applications
GB0402140D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402143D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
TW200628153A (en) 2004-10-05 2006-08-16 Smithkline Beecham Corp Novel compounds

Similar Documents

Publication Publication Date Title
JP2005511532A5 (enExample)
JP2005511531A5 (enExample)
JP2005509622A5 (enExample)
JP2005519932A5 (enExample)
JP2005508962A5 (enExample)
JP2005505618A5 (enExample)
RU2004120553A (ru) Производные никотинамида, полезные в качестве р38-ингибиторов
JP2005508960A5 (enExample)
JP2005508967A5 (enExample)
JP2005535586A5 (enExample)
JP2005538100A5 (enExample)
JP2006523194A5 (enExample)
JP2006523193A5 (enExample)
JP2006524222A5 (enExample)
JP2004517099A5 (enExample)
JP2007501831A5 (enExample)
ATE123771T1 (de) Stickstoff enthaltende heterozyklische verbindungen, ihre herstellung und verwendung.
RU2005105053A (ru) Новые производные пиперидина для применения в лечении болезненных состояний, опосредованных хемокинами
ZA200508158B (en) Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics
JP2006525293A5 (enExample)
RU2004111601A (ru) Пиперидиновые производные и их применение в качестве модуляторов активности р ецепторов хемокина (в частности ccr5)
JP2006523192A5 (enExample)
RU2004121688A (ru) 7-аминобензотиазольные производные в качестве лигандов аденозинового рецептора
JP2005538111A5 (enExample)
RU2004112781A (ru) Производные пиперидина и их применение в качестве модуляторов активности рецепторов хемокинов (в частности ccr5)